Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etravirine

FDA-approved product (tablet, oral), marketed as Etravirine, Intelence.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Etravirine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etravirine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etravirine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Etravirine Plus 2 Analogs in HIV-infected Patients

    NCT01437241 · start 2009-01

    Registered record
    Registry ID
    NCT01437241
    Conditions
    HIV-1-infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-01
    Completion
    2011-09
    Enrolment
    175

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz

    NCT00792584 · start 2008-11

    Registered record
    Registry ID
    NCT00792584
    Conditions
    Sleep Disorders
    Interventions
    etravirine; efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Disorders
    Interventionetravirine; efavirenz
    PhaseNot applicable
    Registry statusCompleted

  • TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

    NCT00740389 · start 2008-09

    Registered record
    Registry ID
    NCT00740389
    Conditions
    HIV; AIDS; Fungal Infection
    Interventions
    TMC125
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2009-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Fungal Infection
    InterventionTMC125
    PhasePhase 1
    Registry statusCompleted

  • TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.

    NCT00767117 · start 2008-09

    Registered record
    Registry ID
    NCT00767117
    Conditions
    HIV
    Interventions
    Etravirine; Lopinavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionEtravirine; Lopinavir; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

    NCT00884793 · start 2008-09

    Registered record
    Registry ID
    NCT00884793
    Conditions
    HIV Infections
    Interventions
    raltegravir; Study NNRTI; Study PI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-09
    Completion
    2010-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionraltegravir; Study NNRTI; Study PI
    PhaseNot applicable
    Registry statusCompleted

  • Kaletra in Combination With Antiretroviral Agents

    NCT01076179 · start 2008-09

    Registered record
    Registry ID
    NCT01076179
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-09
    Completion
    2016-01
    Enrolment
    502

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Sex, Aging and Antiretroviral Pharmacokinetics

    NCT00666055 · start 2008-03

    Registered record
    Registry ID
    NCT00666055
    Conditions
    HIV Infections
    Interventions
    ARV regimen chosen by treating physician
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-03
    Completion
    2012-05
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionARV regimen chosen by treating physician
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

    NCT00534352 · start 2008-01

    Registered record
    Registry ID
    NCT00534352
    Conditions
    HIV-1 Infection
    Interventions
    TMC125; darunavir; ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-03
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionTMC125; darunavir; ritonavir
    PhasePhase 2
    Registry statusCompleted

  • Optimizing Treatment for Treatment-Experienced, HIV-Infected People

    NCT00537394 · start 2008-01

    Registered record
    Registry ID
    NCT00537394
    Conditions
    HIV Infections
    Interventions
    Enfuvirtide; Raltegravir; Darunavir; Tipranavir; Etravirine; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2013-04
    Enrolment
    517

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEnfuvirtide; Raltegravir; Darunavir; Tipranavir +2 more
    PhasePhase 3
    Registry statusCompleted

  • TMC 125 Blood Levels Study

    NCT00531323 · start 2007-09

    Registered record
    Registry ID
    NCT00531323
    Conditions
    HIV Infections
    Interventions
    TMC125 once daily; TMC125 twice daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTMC125 once daily; TMC125 twice daily
    PhasePhase 1
    Registry statusCompleted

  • Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

    NCT00460382 · start 2007-05

    Registered record
    Registry ID
    NCT00460382
    Conditions
    HIV Infections
    Interventions
    raltegravir potassium; darunavir/ritonavir; etravirine; Optimized background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2009-09
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionraltegravir potassium; darunavir/ritonavir; etravirine; Optimized background regimen
    PhasePhase 2
    Registry statusCompleted

  • Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

    NCT00460746 · start 2007-05

    Registered record
    Registry ID
    NCT00460746
    Conditions
    HIV
    Interventions
    TMC125, Darunavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-05
    Completion
    2008-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTMC125, Darunavir; Ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial of CNS-targeted HAART (CIT2)

    NCT00624195 · start 2007-03

    Registered record
    Registry ID
    NCT00624195
    Conditions
    HIV Infections
    Interventions
    FDA Approved Antiretroviral Therapy (see list below)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2012-06
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionFDA Approved Antiretroviral Therapy (see list below)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

    NCT00255099 · start 2005-12

    Registered record
    Registry ID
    NCT00255099
    Conditions
    HIV
    Interventions
    TMC125; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-07
    Enrolment
    593

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTMC125; Placebo
    PhasePhase 3
    Registry statusCompleted